Commentary|Articles|November 17, 2026

Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer

Author(s)OncLive Staff
Fact checked by: Riley Kandel
Listen
0:00 / 0:00

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

The phase 3 SANO trial (NTR6803) found no significant long-term difference in overall survival (OS) between active surveillance and standard esophagectomy for patients with esophageal cancer and a clinical complete response (cCR) to neoadjuvant chemoradiotherapy.1 Distant dissemination occurred more often with surveillance, but a substantial share of patients avoided esophagectomy altogether, according to Sanjiv Gangaram-Panday, MD, PhD.

At a median follow-up of 76 months, 5-year OS rates with active surveillance (n = 198) vs standard surgery (n = 111) did not show a statistically significant difference (HR, 1.17; 95% CI, 0.77-1.77; P = .46). Disease-free survival (DFS) also did not differ significantly between the 2 arms (HR, 1.39; 95% CI, 0.94-2.06; P = .10), however, the 5-year distant dissemination had larger differences (subdistribution HR, 2.04; 95% CI, 1.25-3.34; P < .01).

“Wsee that there’s no statistically significant difference in OS at 5 years between active surveillance and standard surgery in this selected group. We do see a higher rate of distant dissemination in favor of standard surgery. Lastly, we see that 43% of patients [avoided esophagectomy and] actually benefit from active surveillance,” Gangaram-Panday said in an exclusive interview with OncLive®. “We should look at this data combined with the proven noninferiority at 2 years, the benefit in health-related quality of life, the demonstrated cost-effectiveness, and the safety of postponed surgery. We believe that this active surveillance strategy should be an option for patients.”

In the interview, Gangaram-Panday discussed the rationale for active surveillance, the SANO trial design, the 5-year findings presented at the 2026 ESMO Congress, and future research directions.

Gangaram-Panday is a coordinating investigator for the SANO trial in the Department of Surgery at Erasmus University Medical Center in Rotterdam, the Netherlands.

OncLive: Why is it important to evaluate active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in esophageal cancer?

SANO in Esophageal Cancer With a Clinical Complete Response: Take-Home Points

  • Overall survival results at 5 years did not show a statistically significant difference between active surveillance and standard esophagectomy
  • Active surveillance was associated with a higher 5-year distant dissemination rate and more esophageal cancer–related deaths
  • Notably, 5-year DFS rates also did not show a statistically significant difference

Gangaram-Panday: Neoadjuvant chemoradiotherapy followed by esophagectomy has long been a standard treatment for patients with locoregionally advanced esophageal cancer. However, after the [phase 3] CROSS trial [NTR487] results, we already saw that almost 30% [of patients] had a pathological CR.2 Furthermore, we know that almost 30% will have distant dissemination within the first 2 years. Lastly, we also see that postoperative morbidity remains high; almost 60% of patients have complications after esophagectomy, and health-related quality of life [continues] to be worse after esophagectomy. These results combined questioned the benefit of a standard esophagectomy in all patients, which is where the SANO trial was initiated.

What aspects of the SANO trial design and enrollment criteria should clinicians know?

It’s important that it was a stepped-wedge, cluster-randomized design. Randomization was not on [the] patient level but on [the] hospital level. Furthermore, it’s important that it was a noninferiority trial and that it was powered on the 2-year results, because that was the first time that we did the analysis. All analyses [beyond] the power calculation are, of course, secondary, but [they] still remain important.

It was a study [that] was performed in 12 hospitals in the Netherlands, and all patients had a cCR after chemoradiotherapy and had locally advanced esophageal cancer. A cCR was determined with 2 clinical response evaluations: 1 at 6 weeks after chemoradiotherapy, where [patients] had an endoscopy with biopsies, and the second at 12 weeks after chemoradiotherapy. There, they had a PET-CT and endoscopy with biopsies, and [endoscopic ultrasound] with [fine-needle aspiration] if necessary.

If they had a cCR, they underwent either standard surgery or active surveillance. During active surveillance, they repeatedly had the same clinical response evaluations as the second one until they developed a locoregional recurrence, for which they could still undergo a postponed esophagectomy unless they had already metastasized.

What were the 5-year efficacy findings from SANO, and what is their significance?

It’s important to note [that] at the 2-year [analysis], we already saw that [active surveillance] was noninferior in terms of OS. We saw a clear health-related quality of life benefit, even up to 2 years, for dysphagia, and cost-effectiveness has also been demonstrated already. Lastly, we saw similar postoperative complications and 30-day mortality. However, we already saw a numerically higher rate of distant dissemination.

Now at 5 years, 3 years later, we still see that there is no significant difference in OS. It was 50% for active surveillance and 54% for standard surgery. Furthermore, we looked at DFS, which was also not statistically significant. For both, we also looked at histology subtypes; for adenocarcinoma and squamous cell carcinoma, the results were the same, [with] no statistical significance.

Then we looked at the distant dissemination rate. Here, it was clear that active surveillance was doing worse. We had 46% of patients at 5 years with distant dissemination [in the active surveillance group] and 29% in the standard surgery group.

To further explore this paradoxical pattern, because we have no OS difference but we have higher metastasis rates, we looked at the [cause]-specific mortality, [which] was split up by esophageal cancer [death] or not. We saw that it was 40% for active surveillance vs 30% [for standard surgery] for esophageal cancer–related death, [which] was clearly higher for active surveillance. However, it was the other way around for non–cancer-related death, which was 15% for the standard surgery group and 10% in the active surveillance group.

These are all [post hoc] exploratory analyses, but [they are intended] to detect why we find the differences that we find. There won’t be a clear answer for everything, but it’s most likely more [a matter] of small things. For example, in the active surveillance group, there were more PET-CT scans performed, [which] could also have been of influence in the detection of distant dissemination.

Lastly, what happened to all the patients in active surveillance? Of the 198 patients, 51% developed a locoregional regrowth, of which half also still had a distant dissemination after esophagectomy. However, there was also a large group with distant dissemination, which was detected during the clinical response evaluations, [including] 11% [who] had distant dissemination within the first 6 months after chemoradiotherapy. Lastly, 32% had a sustained cCR at the last clinical response evaluations. The 32% [plus] the 11% gives us the 43% hypothesized benefit of active surveillance, [in] which patients avoided esophagectomy.

Were there any notable safety signals with active surveillance vs standard surgery in SANO?

In terms of the clinical response evaluations, we did not see a relevant safety issue with the endoscopy, the endoscopic ultrasound, or the PET-CT scans; we also presented this data earlier. Most importantly, 6 additional patients underwent esophagectomy a lot later, and the postoperative complications and the 30-day and 90-day mortality remained similar. Right now, we don’t see a negative impact in the group that [underwent delayed surgery].

What unanswered questions remain, and how could future research build on SANO?

We believe that what is lacking in the chemoradiotherapy is the systemic [component]. The next steps we are already taking [are that] my colleagues are performing the [phase 2 TNT-OES-2] trial [NCT06161818], a trial where we combine5-fluorouraci, leucovorin, oxaliplatin, and docetaxel [FLOT] and CROSS chemoradiotherapy. We want to see if that increases the [number of] patients [eligible] for active surveillance, but also if they have better outcomes with OS, locoregional regrowth, and distant dissemination.

Furthermore, immunotherapy is one of the next steps we have to take. For this, we are already looking into [whether] patients with a cCR in active surveillance [benefit if] they also receive nivolumab [Opdivo]; that is being performed in the [phase 2] SANO-3 trial [NCT05491616], the outcomes of which will be [available] in December this year. Maybe that will also give a benefit in locoregional regrowth, distant dissemination, and in the end, of course, OS.

Editor’s Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

References

  1. Gangaram-Panday S. Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO). Presented at: European Society for Medical Oncology Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract LBA78.
  2. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084. doi:10.1056/NEJMoa1112088

Related to this article